IOCB Tech

In 2007, the management of ICOB Prague decided to establish its own professional technology transfer office. Following numerous consultations and an independent advisory firm’s evaluation, the institute decided to create a wholly owned subsidiary. The company, named IOCB TTO s.r.o., was founded in 2009 and began its operations on 1 January 2010. In 2017, the company was renamed IOCB Tech s.r.o.

Among IOCB Tech’s primary responsibilities are identifying commercially promising projects at IOCB Prague, analyzing their market potential and patentability, protecting intellectual property, supporting project development through project management, finding commercial partners, and negotiating the terms of licensing agreements.

IOCB Tech has been involved in negotiating and finalizing more than a dozen key licensing agreements with major pharmaceutical partners such as Gilead Sciences, Merck, Novo Nordisk, and SHINE Medical Technologies. In 2019, IOCB Prague’s licensing income reached 2 billion CZK.

The current portfolio includes projects focused on the central nervous system (epilepsy and neuropathic pain), inflammation, cancer, microbial resistance, separation methods, and research tools.

In 2017, the company established the subsidiary i&i Prague, which focuses on funding promising early-stage projects from both the institute and other research and academic institutions.